Intranasal DNA vaccine for protection against respiratory infectious diseases: The delivery perspectives

Pharmaceutics

Volumn 6, Issue 3, 2014, Pages 378-415

  Xu, Yingying ^a   Yuen, Pak Wai ^a   Lam, Jenny Ka Wing ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adjuvants; DNA vaccine; Infectious diseases; Intranasal delivery; Mucosal; Respiratory pathogens

Indexed keywords

CHITOSAN; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOSOME; POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; SWINE INFLUENZA VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; AUTOIMMUNITY; CORONAVIRUS INFECTION; CROSS PROTECTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY INFILTRATE; INFLUENZA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NOSE CAVITY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; TUBERCULOSIS; VACCINATION;

EID: 84904167002     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics6030378     Document Type: Review

References (230)

1. Gurunathan, S.; Klinman, D.M.; Seder, R.A. DNA vaccines: Immunology, application, and optimization. Annu. Rev. Immunol. 2000, 18, 927-974.
2. Bivas-Benita, M.; Ottenhoff, T.H.; Junginger, H.E.; Borchard, G. Pulmonary DNA vaccination: Concepts, possibilities and perspectives. J. Control. Release 2005, 107, 1-29.
3. Donnelly, J.J.; Wahren, B.; Liu, M.A. DNA vaccines: Progress and challenges. J. Immunol. 2005, 175, 633-639.
4. Villarreal, D.O.; Talbott, K.T.; Choo, D.K.; Shedlock, D.J.; Weiner, D.B. Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev. Vaccines 2013, 12, 537-554.
5. Kutzler, M.A.; Weiner, D.B. DNA vaccines: Ready for prime time? Nat. Rev. Genet. 2008, 9, 776-788.
6. Redding, L.; Weiner, D.B. DNA vaccines in veterinary use. Expert Rev. Vaccines 2009, 8, 1251-1276.
7. Davidson, A.H.; Traub-Dargatz, J.L.; Rodeheaver, R.M.; Ostlund, E.N.; Pedersen, D.D.; Moorhead, R.G.; Stricklin, J.B.; Dewell, R.D.; Roach, S.D.; Long, R.E. et al. Immunologic responses to West Nile virus in vaccinated and clinically affected horses. J. Am. Vet. Med. Assoc. 2005, 226, 240-245.
8. Garver, K.A.; LaPatra, S.E.; Kurath, G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis. Aquat. Organ 2005, 64, 13-22.
9. Leitner, W.W.; Ying, H.; Restifo, N.P. DNA and RNA-based vaccines: Principles, progress and prospects. Vaccine 1999, 18, 765-777.
10. Manickan, E.; Karem, K.L.; Rouse, B.T. DNA vaccines-A modern gimmick or a boon to vaccinology? Crit. Rev. Immunol. 1997, 17, 135-154.
11. Kalams, S.A.; Parker, S.; Jin, X.; Elizaga, M.; Metch, B.; Wang, M.; Hural, J.; Lubeck, M.; Eldridge, J.; Cardinali, M. et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012, 7, e29231.
12. McConkey, S.J.; Reece, W.H.; Moorthy, V.S.; Webster, D.; Dunachie, S.; Butcher, G.; Vuola, J.M.; Blanchard, T.J.; Gothard, P.; Watkins, K. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 2003, 9, 729-735.
13. Mwau, M.; Cebere, I.; Sutton, J.; Chikoti, P.; Winstone, N.; Wee, E.G.-T.; Beattie, T.; Chen, Y.-H.; Dorrell, L.; McShane, H. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: Stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 2004, 85, 911-919.
14. Jaoko, W.; Nakwagala, F.N.; Anzala, O.; Manyonyi, G.O.; Birungi, J.; Nanvubya, A.; Bashir, F.; Bhatt, K.; Ogutu, H.; Wakasiaka, S. et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008, 26, 2788-2795.
15. McCormack, S.; Stohr, W.; Barber, T.; Bart, P.A.; Harari, A.; Moog, C.; Ciuffreda, D.; Cellerai, C.; Cowen, M.; Gamboni, R. et al. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26, 3162-3174.
16. Li, L.; Saade, F.; Petrovsky, N. The future of human DNA vaccines. J. Biotechnol. 2012, 162, 171-182.
17. Leifert, J.A.; Whitton, J.L. Immune responses to DNA vaccines: Induction of CD8 T Cells. In DNA Vaccines; Landes Bioscience: Austin, TX, USA, 2000; pp. 82-104.
18. Timares, L.; Takashima, A.; Johnston, S.A. Quantitative analysis of the immunopotency of genetically transfected dendritic cells. Proc. Natl. Acad. Sci. USA 1998, 95, 13147-13152.
19. Torres, C.; Iwasaki, A.; Barber, B.H.; Robinson, H.L. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J. Immunol. 1997, 158, 4529-4532.
20. Dalpke, A.; Zimmermann, S.; Heeg, K. CpG-oligonucleotides in vaccination: Signaling and mechanisms of action. Immunobiology 2001, 204, 667-676.
21. Bode, C.; Zhao, G.; Steinhagen, F.; Kinjo, T.; Klinman, D.M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 2011, 10, 499-511.
22. +/+ mice display similar immune responses to a DNA vaccine. Immunology 2004, 113, 114-120.
23. Tudor, D.; Dubuquoy, C.; Gaboriau, V.; Lefevre, F.; Charley, B.; Riffault, S. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine 2005, 23, 1258-1264.
24. Ishii, K.J.; Kawagoe, T.; Koyama, S.; Matsui, K.; Kumar, H.; Kawai, T.; Uematsu, S.; Takeuchi, O.; Takeshita, F.; Coban, C. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008, 451, 725-729.
25. Ishikawa, H.; Ma, Z.; Barber, G.N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009, 461, 788-792.
26. Wilson, E.B.; Yamada, D.H.; Elsaesser, H.; Herskovitz, J.; Deng, J.; Cheng, G.; Aronow, B.J.; Karp, C.L.; Brooks, D.G. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340, 202-207.
27. Swain, S.L. Class II-independent generation of CD4 memory T cells from effectors. Science 1999, 286, 1381-1383.
28. Ducatez, M.F.; Bahl, J.; Griffin, Y.; Stigger-Rosser, E.; Franks, J.; Barman, S.; Vijaykrishna, D.; Webb, A.; Guan, Y.; Webster, R.G. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc. Natl. Acad. Sci. USA 2011, 108, 349-354.
29. Ogunremi, O.; Pasick, J.; Kobinger, G.P.; Hannaman, D.; Berhane, Y.; Clavijo, A. A single electroporation delivery of a DNA vaccine containing the hemagglutinin gene of Asian H5N1 avian influenza virus generated a protective antibody response in chickens against a North American virus strain. Clin. Vaccine Immunol. 2013, 20, 491-500.
30. Belshe, R.B.; Mendelman, P.M.; Treanor, J.; King, J.; Gruber, W.C.; Piedra, P.; Bernstein, D.I.; Hayden, F.G.; Kotloff, K.; Zangwill, K. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 1998, 338, 1405-1412.
31. Gruber, W.C. The role of live influenza vaccines in children. Vaccine 2002, 20, S66-S73.
32. Jones, S.; Evans, K.; McElwaine-Johnn, H.; Sharpe, M.; Oxford, J.; Lambkin-Williams, R.; Mant, T.; Nolan, A.; Zambon, M.; Ellis, J. et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009, 27, 2506-2512.
33. Nichols, W.W.; Ledwith, B.J.; Manam, S.V.; Troilo, P.J. Potential DNA vaccine integration into host cell genome. Ann. N. Y. Acad. Sci. 1995, 772, 30-39.
34. Sheets, R.L.; Stein, J.; Manetz, T.S.; Duffy, C.; Nason, M.; Andrews, C.; Kong, W.P.; Nabel, G.J.; Gomez, P.L. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol. Sci. 2006, 91, 610-619.
35. Ledwith, B.J.; Manam, S.; Troilo, P.J.; Barnum, A.B.; Pauley, C.J.; Griffiths, T.G., II; Harper, L.B.; Schock, H.B.; Zhang, H.; Faris, J.E. et al. Plasmid DNA vaccines: Assay for integration into host genomic DNA. Dev. Biol. 2000, 104, 33-43.
36. Wang, Z.; Troilo, P.J.; Wang, X.; Griffiths, T.G.; Pacchione, S.J.; Barnum, A.B.; Harper, L.B.; Pauley, C.J.; Niu, Z.; Denisova, L. et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 2004, 11, 711-721.
37. Tavel, J.A.; Martin, J.E.; Kelly, G.G.; Enama, M.E.; Shen, J.M.; Gomez, P.L.; Andrews, C.A.; Koup, R.A.; Bailer, R.T.; Stein, J.A. et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J. Acquir. Immune Defic. Syndr. 2007, 44, 601-605.
38. MacGregor, R.R.; Boyer, J.D.; Ugen, K.E.; Lacy, K.E.; Gluckman, S.J.; Bagarazzi, M.L.; Chattergoon, M.A.; Baine, Y.; Higgins, T.J.; Ciccarelli, R.B. et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J. Infect. Dis. 1998, 178, 92-100.
39. Le, T.P.; Coonan, K.M.; Hedstrom, R.C.; Charoenvit, Y.; Sedegah, M.; Epstein, J.E.; Kumar, S.; Wang, R.; Doolan, D.L.; Maguire, J.D. et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000, 18, 1893-1901.
40. Xiang, Z.Q.; Spitalnik, S.L.; Cheng, J.; Erikson, J.; Wojczyk, B.; Ertl, H.C. Immune responses to nucleic acid vaccines to rabies virus. Virology 1995, 209, 569-579.
41. Mairhofer, J.; Pfaffenzeller, I.; Merz, D.; Grabherr, R. A novel antibiotic free plasmid selection system: Advances in safe and efficient DNA therapy. Biotechnol. J. 2008, 3, 83-89.
42. Silverstein, A.M.; Segal, S. The ontogeny of antigen-specific T cells. J. Exp. Med. 1975, 142, 802-804.
43. Prince, A.M.; Whalen, R.; Brotman, B. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine 1997, 15, 916-919.
44. Bot, A.; Bot, S.; Bona, C. Enhanced protection against influenza virus of mice immunized as newborns with a mixture of plasmids expressing hemagglutinin and nucleoprotein. Vaccine 1998, 16, 1675-1682.
45. Gherardi, R.K.; Authier, F.J. Macrophagic myofasciitis: Characterization and pathophysiology. Lupus 2012, 21, 184-189.
46. Lanza, G.A.; Barone, L.; Scalone, G.; Pitocco, D.; Sgueglia, G.A.; Mollo, R.; Nerla, R.; Zaccardi, F.; Ghirlanda, G.; Crea, F. Inflammation-related effects of adjuvant influenza A vaccination on platelet activation and cardiac autonomic function. J. Intern. Med. 2011, 269, 118-125.
47. Christian, L.M.; Iams, J.D.; Porter, K.; Glaser, R. Inflammatory responses to trivalent influenza virus vaccine among pregnant women. Vaccine 2011, 29, 8982-8987.
48. Liuba, P.; Aburawi, E.H.; Pesonen, E.; Andersson, S.; Truedsson, L.; Yla-Herttuala, S.; Holmberg, L. Residual adverse changes in arterial endothelial function and LDL oxidation after a mild systemic inflammation induced by influenza vaccination. Ann. Med. 2007, 39, 392-399.
49. Ramakrishnan, A.; Althoff, K.N.; Lopez, J.A.; Coles, C.L.; Bream, J.H. Differential serum cytokine responses to inactivated and live attenuated seasonal influenza vaccines. Cytokine 2012, 60, 661-666.
50. Babiuk, S.; Baca-Estrada, M.E.; Foldvari, M.; Middleton, D.M.; Rabussay, D.; Widera, G.; Babiuk, L.A. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J. Biotechnol. 2004, 110, 1-10.
51. Goepfert, P.A.; Elizaga, M.L.; Sato, A.; Qin, L.; Cardinali, M.; Hay, C.M.; Hural, J.; DeRosa, S.C.; DeFawe, O.D.; Tomaras, G.D. et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J. Infect. Dis. 2011, 203, 610-619.
52. Smith, L.R.; Wloch, M.K.; Ye, M.; Reyes, L.R.; Boutsaboualoy, S.; Dunne, C.E.; Chaplin, J.A.; Rusalov, D.; Rolland, A.P.; Fisher, C.L. et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010, 28, 2565-2572.
53. Wolchok, J.D.; Yuan, J.; Houghton, A.N.; Gallardo, H.F.; Rasalan, T.S.; Wang, J.; Zhang, Y.; Ranganathan, R.; Chapman, P.B.; Krown, S.E. et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol. Ther. 2007, 15, 2044-2050.
54. Ledgerwood, J.E.; Wei, C.J.; Hu, Z.; Gordon, I.J.; Enama, M.E.; Hendel, C.S.; McTamney, P.M.; Pearce, M.B.; Yassine, H.M.; Boyington, J.C. DNA priming and influenza vaccine immunogenicity: Two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 2011, 11, 916-924.
55. Neutra, M.R.; Pringault, E.; Kraehenbuhl, J.P. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu. Rev. Immunol. 1996, 14, 275-300.
56. Neutra, M.R.; Kozlowski, P.A. Mucosal vaccines: The promise and the challenge. Nat. Rev. Immunol. 2006, 6, 148-158.
57. Brandtzaeg, P. Function of mucosa-associated lymphoid tissue in antibody formation. Immunol. Invest. 2010, 39, 303-355.
58. Lycke, N. Recent progress in mucosal vaccine development: Potential and limitations. Nat. Rev. Immunol. 2012, 12, 592-605.
59. Carter, N.J.; Curran, M.P. Live attenuated influenza vaccine (FluMist(R); Fluenz): A review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011, 71, 1591-1622.
60. Dhere, R.; Yeolekar, L.; Kulkarni, P.; Menon, R.; Vaidya, V.; Ganguly, M.; Tyagi, P.; Barde, P.; Jadhav, S. A pandemic influenza vaccine in India: From strain to sale within 12 months. Vaccine 2011, 29, A16-A21.
61. Briles, D.E.; Ades, E.; Paton, J.C.; Sampson, J.S.; Carlone, G.M.; Huebner, R.C.; Virolainen, A.; Swiatlo, E.; Hollingshead, S.K. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect. Immun. 2000, 68, 796-800.
62. Rigter, A.; Widjaja, I.; Versantvoort, H.; Coenjaerts, F.E.; van Roosmalen, M.; Leenhouts, K.; Rottier, P.J.; Haijema, B.J.; de Haan, C.A. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One 2013, 8, e71072.
63. Csaba, N.; Garcia-Fuentes, M.; Alonso, M.J. Nanoparticles for nasal vaccination. Adv. Drug Deliv. Rev. 2009, 61, 140-157.
64. Bienenstock, J.; McDermott, M.R. Bronchus- and nasal-associated lymphoid tissues. Immunol. Rev. 2005, 206, 22-31.
65. Wu, Y.; Wang, X.; Csencsits, K.L.; Haddad, A.; Walters, N.; Pascual, D.W. M cell-targeted DNA vaccination. Proc. Natl. Acad. Sci. USA 2001, 98, 9318-9323.
66. Woodrow, K.A.; Bennett, K.M.; Lo, D.D. Mucosal vaccine design and delivery. Annu. Rev. Biomed. Eng. 2012, 14, 17-46.
67. Lamm, M.E. Interaction of antigens and antibodies at mucosal surfaces. Annu. Rev. Microbiol. 1997, 51, 311-340.
68. Moldoveanu, Z.; Clements, M.L.; Prince, S.J.; Murphy, B.R.; Mestecky, J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995, 13, 1006-1012.
69. Kaliner, M.; Shelhamer, J.H.; Borson, B.; Nadel, J.; Patow, C.; Marom, Z. Human respiratory mucus. Am. Rev. Respir. Dis. 1986, 134, 612-621.
70. Couch, R.B. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N. Engl. J. Med. 2004, 350, 860-861.
71. Lewis, D.J.; Huo, Z.; Barnett, S.; Kromann, I.; Giemza, R.; Galiza, E.; Woodrow, M.; Thierry-Carstensen, B.; Andersen, P.; Novicki, D. et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4, e6999.
72. Eriksson, A.M.; Schon, K.M.; Lycke, N.Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 2004, 173, 3310-3319.
73. Hagiwara, Y.; Kawamura, Y.I.; Kataoka, K.; Rahima, B.; Jackson, R.J.; Komase, K.; Dohi, T.; Boyaka, P.N.; Takeda, Y.; Kiyono, H. et al. A second generation of double mutant cholera toxin adjuvants: Enhanced immunity without intracellular trafficking. J. Immunol. 2006, 177, 3045-3054.
74. Gupta, U.D.; Katoch, V.M.; McMurray, D.N. Current status of TB vaccines. Vaccine 2007, 25, 3742-3751.
75. Stenger, S.; Modlin, R.L. T cell mediated immunity to Mycobacterium tuberculosis. Curr. Opin. Microbiol. 1999, 2, 89-93.
76. +-T-cell epitopes from antigen 85A. Infect. Immun. 2002, 70, 1623-1626.
77. Okada, M.; Kita, Y. Tuberculosis vaccine development: The development of a novel (preclinical) DNA vaccine. Hum. Vaccines 2010, 6, 297-308.
78. Huygen, K.; Content, J.; Denis, O.; Montgomery, D.L.; Yawman, A.M.; Deck, R.R.; DeWitt, C.M.; Orme, I.M.; Baldwin, S.; D'Souza, C. et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 1996, 2, 893-898.
79. Tascon, R.E.; Colston, M.J.; Ragno, S.; Stavropoulos, E.; Gregory, D.; Lowrie, D.B. Vaccination against tuberculosis by DNA injection. Nat. Med. 1996, 2, 888-892.
80. Lozes, E.; Huygen, K.; Content, J.; Denis, O.; Montgomery, D.L.; Yawman, A.M.; Vandenbussche, P.; van Vooren, J.P.; Drowart, A.; Ulmer, J.B. et al. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 1997, 15, 830-833.
81. Tian, X.; Cai, H.; Zhu, Y.X. Protection of mice with a divalent tuberculosis DNA vaccine encoding antigens Ag85B and MPT64. Acta Biochim. Biophys. Sin. 2004, 36, 269-276.
82. Derrick, S.C.; Yang, A.L.; Morris, S.L. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 2004, 23, 780-788.
83. Zhu, D.; Jiang, S.; Luo, X. Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection. Vaccine 2005, 23, 4619-4624.
84. Wozniak, T.M.; Ryan, A.A.; Triccas, J.A.; Britton, W.J. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect. Immun. 2006, 74, 557-565.
85. Yuan, W.; Dong, N.; Zhang, L.; Liu, J.; Lin, S.; Xiang, Z.; Qiao, H.; Tong, W.; Qin, C. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice. Vaccine 2012, 30, 2490-2497.
86. Graham, R.L.; Donaldson, E.F.; Baric, R.S. A decade after SARS: Strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 2013, 11, 836-848.
87. Bolles, M.; Deming, D.; Long, K.; Agnihothram, S.; Whitmore, A.; Ferris, M.; Funkhouser, W.; Gralinski, L.; Totura, A.; Heise, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 2011, 85, 12201-12215.
88. Woo, P.C.; Lau, S.K.; Tsoi, H.W.; Chen, Z.W.; Wong, B.H.; Zhang, L.; Chan, J.K.; Wong, L.P.; He, W.; Ma, C. et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 2005, 23, 4959-4968.
89. Yang, Z.Y.; Kong, W.P.; Huang, Y.; Roberts, A.; Murphy, B.R.; Subbarao, K.; Nabel, G.J. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004, 428, 561-564.
90. Gupta, V.; Tabiin, T.M.; Sun, K.; Chandrasekaran, A.; Anwar, A.; Yang, K.; Chikhlikar, P.; Salmon, J.; Brusic, V.; Marques, E.T. et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology 2006, 347, 127-139.
91. Zhao, P.; Cao, J.; Zhao, L.J.; Qin, Z.L.; Ke, J.S.; Pan, W.; Ren, H.; Yu, J.G.; Qi, Z.T. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology 2005, 331, 128-135.
92. Garten, R.J.; Davis, C.T.; Russell, C.A.; Shu, B.; Lindstrom, S.; Balish, A.; Sessions, W.M.; Xu, X.; Skepner, E.; Deyde, V. et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325, 197-201.
93. Abdel-Ghafar, A.N.; Chotpitayasunondh, T.; Gao, Z.; Hayden, F.G.; Nguyen, D.H.; de Jong, M.D.; Naghdaliyev, A.; Peiris, J.S.; Shindo, N.; Soeroso, S. et al. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 2008, 358, 261-273.
94. Epstein, S.L.; Tumpey, T.M.; Misplon, J.A.; Lo, C.Y.; Cooper, L.A.; Subbarao, K.; Renshaw, M.; Sambhara, S.; Katz, J.M. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg. Infect. Dis. 2002, 8, 796-801.
95. Epstein, S.L.; Kong, W.P.; Misplon, J.A.; Lo, C.Y.; Tumpey, T.M.; Xu, L.; Nabel, G.J. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23, 5404-5410.
96. Ferraro, B.; Morrow, M.P.; Hutnick, N.A.; Shin, T.H.; Lucke, C.E.; Weiner, D.B. Clinical applications of DNA vaccines: Current progress. Clin. Infect. Dis. 2011, 53, 296-302.
97. Chen, Z.; Matsuo, K.; Asanuma, H.; Takahashi, H.; Iwasaki, T.; Suzuki, Y.; Aizawa, C.; Kurata, T.; Tamura, S. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Vaccine 1999, 17, 653-659.
98. Donnelly, J.J.; Friedman, A.; Martinez, D.; Montgomery, D.L.; Shiver, J.W.; Motzel, S.L.; Ulmer, J.B.; Liu, M.A. Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus. Nat. Med. 1995, 1, 583-587.
99. Donnelly, J.J.; Friedman, A.; Ulmer, J.B.; Liu, M.A. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 1997, 15, 865-868.
100. Chen, Q.; Kuang, H.; Wang, H.; Fang, F.; Yang, Z.; Zhang, Z.; Zhang, X.; Chen, Z. Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 2009, 38, 30-38.
101. Drape, R.J.; Macklin, M.D.; Barr, L.J.; Jones, S.; Haynes, J.R.; Dean, H.J. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006, 24, 4475-4481.
102. Collins, P.L.; Hill, M.G.; Johnson, P.R. The two open reading frames of the 22k mRNA of human respiratory syncytial virus: Sequence comparison of antigenic subgroups A and B and expression in vitro. J. Gen. Virol. 1990, 71, 3015-3020.
103. Falsey, A.R.; Hennessey, P.A.; Formica, M.A.; Cox, C.; Walsh, E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 2005, 352, 1749-1759.
104. Martinez, X.; Li, X.; Kovarik, J.; Klein, M.; Lambert, P.H.; Siegrist, C.A. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice. Eur. J. Immunol. 1999, 29, 3390-3400.
105. Johnson, P.R.; Collins, P.L. The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: Sequence conservation provides a structural basis for antigenic relatedness. J. Gen. Virol. 1988, 69, 2623-2628.
106. Li, X.; Sambhara, S.; Li, C.X.; Ewasyshyn, M.; Parrington, M.; Caterini, J.; James, O.; Cates, G.; Du, R.P.; Klein, M. Protection against respiratory syncytial virus infection by DNA immunization. J. Exp. Med. 1998, 188, 681-688.
107. Ternette, N.; Tippler, B.; Uberla, K.; Grunwald, T. Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 2007, 25, 7271-7279.
108. Li, X.; Sambhara, S.; Li, C.X.; Ettorre, L.; Switzer, I.; Cates, G.; James, O.; Parrington, M.; Oomen, R.; Du, R.P. et al. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 2000, 269, 54-65.
109. + T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J. Virol. 1992, 66, 1277-1281.
110. Boyoglu, S.; Vig, K.; Pillai, S.; Rangari, V.; Dennis, V.A.; Khazi, F.; Singh, S.R. Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus. Nanomedicine 2009, 5, 463-472.
111. Barnum, S.; Subbarayan, P.; Vig, K.; Pillai, S.; Dennis, V. Nano-encapsulated DNA and/or protein boost immunizations increase efficiency of DNA vaccine protection against RSV. J. Nanomed. Nanotechnol. 2012, 3, 1000132.
112. Dupuis, M.; Denis-Mize, K.; Woo, C.; Goldbeck, C.; Selby, M.J.; Chen, M.; Otten, G.R.; Ulmer, J.B.; Donnelly, J.J.; Ott, G. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J. Immunol. 2000, 165, 2850-2858.
113. Fynan, E.F.; Webster, R.G.; Fuller, D.H.; Haynes, J.R.; Santoro, J.C.; Robinson, H.L. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA 1993, 90, 11478-11482.
114. Pertmer, T.M.; Eisenbraun, M.D.; McCabe, D.; Prayaga, S.K.; Fuller, D.H.; Haynes, J.R. Gene gun-based nucleic acid immunization: Elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 1995, 13, 1427-1430.
115. Yoshida, A.; Nagata, T.; Uchijima, M.; Higashi, T.; Koide, Y. Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses. Vaccine 2000, 18, 1725-1729.
116. Banchereau, J.; Briere, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y.J.; Pulendran, B.; Palucka, K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18, 767-811.
117. Mellman, I.; Steinman, R.M. Dendritic cells: Specialized and regulated antigen processing machines. Cell 2001, 106, 255-258.
118. Steinman, R.M. Dendritic cells in vivo: A key target for a new vaccine science. Immunity 2008, 29, 319-324.
119. Foged, C.; Sundblad, A.; Hovgaard, L. Targeting vaccines to dendritic cells. Pharm. Res. 2002, 19, 229-238.
120. Wang, W.W.; Das, D.; Suresh, M.R. A versatile bifunctional dendritic cell targeting vaccine vector. Mol. Pharm. 2009, 6, 158-172.
121. + T cells. Proc. Natl. Acad. Sci. USA 2010, 107, 4281-4286.
122. Raghuwanshi, D.; Mishra, V.; Das, D.; Kaur, K.; Suresh, M.R. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein. Mol. Pharm. 2012, 9, 946-956.
123. Caminschi, I.; Proietto, A.I.; Ahmet, F.; Kitsoulis, S.; Shin Teh, J.; Lo, J.C.; Rizzitelli, A.; Wu, L.; Vremec, D.; van Dommelen, S.L. et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 2008, 112, 3264-3273.
124. Shortman, K.; Lahoud, M.H.; Caminschi, I. Improving vaccines by targeting antigens to dendritic cells. Exp. Mol. Med. 2009, 41, 61-66.
125. Brasel, K.; McKenna, H.J.; Morrissey, P.J.; Charrier, K.; Morris, A.E.; Lee, C.C.; Williams, D.E.; Lyman, S.D. Hematologic effects of flt3 ligand in vivo in mice. Blood 1996, 88, 2004-2012.
126. Maraskovsky, E.; Brasel, K.; Teepe, M.; Roux, E.R.; Lyman, S.D.; Shortman, K.; McKenna, H.J. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 1996, 184, 1953-1962.
127. Williamson, E.; Westrich, G.M.; Viney, J.L. Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol. 1999, 163, 3668-3675.
128. Hung, C.F.; Hsu, K.F.; Cheng, W.F.; Chai, C.Y.; He, L.; Ling, M.; Wu, T.C. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res. 2001, 61, 1080-1088.
129. + dendritic cells for enhanced mucosal immunity. J. Immunol. 2004, 172, 3612-3619.
130. Kataoka, K.; Fujihashi, K.; Oma, K.; Fukuyama, Y.; Hollingshead, S.K.; Sekine, S.; Kawabata, S.; Ito, H.O.; Briles, D.E.; Oishi, K. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Infect. Immun. 2011, 79, 2819-2828.
131. Ermak, T.H.; Dougherty, E.P.; Bhagat, H.R.; Kabok, Z.; Pappo, J. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells. Cell Tissue Res. 1995, 279, 433-436.
132. Shakweh, M.; Besnard, M.; Nicolas, V.; Fattal, E. Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by Peyer's patches in mice. Eur. J. Pharm. Biopharm. 2005, 61, 1-13.
133. Gupta, P.N.; Khatri, K.; Goyal, A.K.; Mishra, N.; Vyas, S.P. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target. 2007, 15, 701-713.
134. Rajapaksa, T.E.; Stover-Hamer, M.; Fernandez, X.; Eckelhoefer, H.A.; Lo, D.D. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J. Control. Release 2010, 142, 196-205.
135. Sharma, S.; Mukkur, T.K.; Benson, H.A.; Chen, Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J. Pharm. Sci. 2009, 98, 812-843.
136. Reddy, S.T.; van der Vlies, A.J.; Simeoni, E.; Angeli, V.; Randolph, G.J.; O'Neil, C.P.; Lee, L.K.; Swartz, M.A.; Hubbell, J.A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25, 1159-1164.
137. Manocha, M.; Pal, P.C.; Chitralekha, K.T.; Thomas, B.E.; Tripathi, V.; Gupta, S.D.; Paranjape, R.; Kulkarni, S.; Rao, D.N. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 2005, 23, 5599-5617.
138. Wolf, J.L.; Rubin, D.H.; Finberg, R.; Kauffman, R.S.; Sharpe, A.H.; Trier, J.S.; Fields, B.N. Intestinal M cells: A pathway for entry of reovirus into the host. Science 1981, 212, 471-472.
139. Jones, B.D.; Ghori, N.; Falkow, S. Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. J. Exp. Med. 1994, 180, 15-23.
140. Teitelbaum, R.; Schubert, W.; Gunther, L.; Kress, Y.; Macaluso, F.; Pollard, J.W.; McMurray, D.N.; Bloom, B.R. The M cell as a portal of entry to the lung for the bacterial pathogen Mycobacterium tuberculosis. Immunity 1999, 10, 641-650.
141. Fujkuyama, Y.; Tokuhara, D.; Kataoka, K.; Gilbert, R.S.; McGhee, J.R.; Yuki, Y.; Kiyono, H.; Fujihashi, K. Novel vaccine development strategies for inducing mucosal immunity. Expert Rev. Vaccines 2012, 11, 367-379.
142. Kim, S.H.; Seo, K.W.; Kim, J.; Lee, K.Y.; Jang, Y.S. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. J. Immunol. 2010, 185, 5787-5795.
143. Lo, D.D.; Ling, J.; Eckelhoefer, A.H. M cell targeting by a Claudin 4-targeting peptide can enhance mucosal IgA responses. BMC Biotechnol. 2012, 12, 7.
144. Nochi, T.; Yuki, Y.; Matsumura, A.; Mejima, M.; Terahara, K.; Kim, D.Y.; Fukuyama, S.; Iwatsuki-Horimoto, K.; Kawaoka, Y.; Kohda, T. et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J. Exp. Med. 2007, 204, 2789-2796.
145. Rynda, A.; Maddaloni, M.; Mierzejewska, D.; Ochoa-Reparaz, J.; Maslanka, T.; Crist, K.; Riccardi, C.; Barszczewska, B.; Fujihashi, K.; McGhee, J.R. et al. Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1. J. Immunol. 2008, 180, 5187-5200.
146. Boussif, O.; Lezoualc'h, F.; Zanta, M.A.; Mergny, M.D.; Scherman, D.; Demeneix, B.; Behr, J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. USA 1995, 92, 7297-7301.
147. Shim, B.S.; Park, S.M.; Quan, J.S.; Jere, D.; Chu, H.; Song, M.K.; Kim, D.W.; Jang, Y.S.; Yang, M.S.; Han, S.H. et al. Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses. BMC Immunol. 2010, 11, 65.
148. Torrieri-Dramard, L.; Lambrecht, B.; Ferreira, H.L.; van den Berg, T.; Klatzmann, D.; Bellier, B. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol. Ther. 2011, 19, 602-611.
149. Mann, J.F.; McKay, P.F.; Arokiasamy, S.; Patel, R.K.; Klein, K.; Shattock, R.J. Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection. J. Control. Release 2013, 170, 452-459.
150. Kang, M.L.; Cho, C.S.; Yoo, H.S. Application of chitosan microspheres for nasal delivery of vaccines. Biotechnol. Adv. 2009, 27, 857-865.
151. Mao, S.; Sun, W.; Kissel, T. Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Deliv. Rev. 2010, 62, 12-27.
152. Illum, L.; Davis, S.S. Nasal vaccination: A non-invasive vaccine delivery method that holds great promise for the future. Adv. Drug Deliv. Rev. 2001, 51, 81.
153. Issa, M.M.; Köping-Höggård, M.; Artursson, P. Chitosan and the mucosal delivery of biotechnology drugs. Drug Discov. Today 2005, 2, 1-6.
154. Casettari, L.; Vllasaliu, D.; Lam, J.K.; Soliman, M.; Illum, L. Biomedical applications of amino acid-modified chitosans: A review. Biomaterials 2012, 33, 7565-7583.
155. Seferian, P.G.; Martinez, M.L. Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine 2000, 19, 661-668.
156. Kumar, M.; Behera, A.K.; Lockey, R.F.; Zhang, J.; Bhullar, G.; de La Cruz, C.P.; Chen, L.C.; Leong, K.W.; Huang, S.K.; Mohapatra, S.S. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum. Gene Ther. 2002, 13, 1415-1425.
157. Iqbal, M.; Lin, W.; Jabbal-Gill, I.; Davis, S.; Steward, M.; Illum, L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 2003, 21, 1478-1485.
158. Bernkop-Schnurch, A.; Hornof, M.; Guggi, D. Thiolated chitosans. Eur. J. Pharm. Biopharm. 2004, 57, 9-17.
159. Lee, D.; Zhang, W.; Shirley, S.A.; Kong, X.; Hellermann, G.R.; Lockey, R.F.; Mohapatra, S.S. Thiolated chitosan/DNA nanocomplexes exhibit enhanced and sustained gene delivery. Pharm. Res. 2007, 24, 157-167.
160. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55, 329-347.
161. Bivas-Benita, M.; Romeijn, S.; Junginger, H.E.; Borchard, G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur. J. Pharm. Biopharm. 2004, 58, 1-6.
162. Nafee, N.; Taetz, S.; Schneider, M.; Schaefer, U.F.; Lehr, C.M. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: Effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 2007, 3, 173-183.
163. Bordelon, H.; Biris, A.S.; Sabliov, C.M.; Todd Monroe, W. Characterization of plasmid DNA location within Chitosan/PLGA/pDNA nanoparticle complexes designed for gene delivery. J. Nanomater. 2011, 2011, 1-9.
164. Tahara, K.; Sakai, T.; Yamamoto, H.; Takeuchi, H.; Kawashima, Y. Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int. J. Pharm. 2008, 354, 210-216.
165. Oster, C.G.; Kim, N.; Grode, L.; Barbu-Tudoran, L.; Schaper, A.K.; Kaufmann, S.H.; Kissel, T. Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination. J. Control. Release 2005, 104, 359-377.
166. Wang, G.; Pan, L.; Zhang, Y.; Wang, Y.; Zhang, Z.; Lü, J.; Zhou, P.; Fang, Y.; Jiang, S. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge. PLoS One 2011, 6, e27605.
167. Ravi Kumar, M.N.; Bakowsky, U.; Lehr, C.M. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004, 25, 1771-1777.
168. Bu, J.; Song, Y.; Rompato, G.; Burgess, D.J.; Garmendia, A.E. Co-delivery of IL-2 or liposomes augment the responses of mice to a DNA vaccine for pseudorabies virus IE180. Comp. Immunol. Microbiol. Infect. Dis. 2003, 26, 175-187.
169. Jiao, X.; Wang, R.Y.; Feng, Z.; Alter, H.J.; Shih, J.W. Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology 2003, 37, 452-460.
170. Yoshikawa, T.; Imazu, S.; Gao, J.Q.; Hayashi, K.; Tsuda, Y.; Shimokawa, M.; Sugita, T.; Niwa, T.; Oda, A.; Akashi, M. et al. Augmentation of antigen-specific immune responses using DNA-fusogenic liposome vaccine. Biochem. Biophys. Res. Commun. 2004, 325, 500-505.
171. Brito, L.A.; Malyala, P.; O'Hagan, D.T. Vaccine adjuvant formulations: A pharmaceutical perspective. Semin. Immunol. 2013, 25, 130-145.
172. Legendre, J.Y.; Szoka, F.C., Jr. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: Comparison with cationic liposomes. Pharm. Res. 1992, 9, 1235-1242.
173. Khatri, K.; Goyal, A.K.; Gupta, P.N.; Mishra, N.; Mehta, A.; Vyas, S.P. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008, 26, 2225-2233.
174. Lay, M.; Callejo, B.; Chang, S.; Hong, D.K.; Lewis, D.B.; Carroll, T.D.; Matzinger, S.; Fritts, L.; Miller, C.J.; Warner, J.F. et al. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 2009, 27, 3811-3820.
175. D'Souza, S.; Rosseels, V.; Denis, O.; Tanghe, A.; de Smet, N.; Jurion, F.; Palfliet, K.; Castiglioni, N.; Vanonckelen, A.; Wheeler, C. et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect. Immun. 2002, 70, 3681-3688.
176. Rosada, R.S.; de la Torre, L.G.; Frantz, F.G.; Trombone, A.P.; Zarate-Blades, C.R.; Fonseca, D.M.; Souza, P.R.; Brandao, I.T.; Masson, A.P.; Soares, E.G. et al. Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunol. 2008, 9, 38.
177. Wong, J.P.; Zabielski, M.A.; Schmaltz, F.L.; Brownlee, G.G.; Bussey, L.A.; Marshall, K.; Borralho, T.; Nagata, L.P. DNA vaccination against respiratory influenza virus infection. Vaccine 2001, 19, 2461-2467.
178. Wang, D.; Christopher, M.E.; Nagata, L.P.; Zabielski, M.A.; Li, H.; Wong, J.P.; Samuel, J. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J. Clin. Virol. 2004, 31S, 99-106.
179. Gogev, S.; de Fays, K.; Versali, M.F.; Gautier, S.; Thiry, E. Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1. Vaccine 2004, 22, 1946-1953.
180. Kataoka, K.; Fujihashi, K. Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines. Expert Rev. Vaccines 2009, 8, 1183-1193.
181. Fraser, C.K.; Diener, K.R.; Brown, M.P.; Hayball, J.D. Improving vaccines by incorporating immunological coadjuvants. Expert Rev. Vaccines 2007, 6, 559-578.
182. Vajdy, M.; Srivastava, I.; Polo, J.; Donnelly, J.; O'Hagan, D.; Singh, M. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol. Cell. Biol. 2004, 82, 617-627.
183. Ryan, E.J.; McNeela, E.; Murphy, G.A.; Stewart, H.; O'Hagan, D.; Pizza, M.; Rappuoli, R.; Mills, K.H. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 1999, 67, 6270-6280.
184. Jakobsen, H.; Schulz, D.; Pizza, M.; Rappuoli, R.; Jonsdottir, I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect. Immun. 1999, 67, 5892-5897.
185. Neidleman, J.A.; Vajdy, M.; Ugozzoli, M.; Ott, G.; O'Hagan, D. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55. Immunology 2000, 101, 154-160.
186. Fujihashi, K.; Koga, T.; van Ginkel, F.W.; Hagiwara, Y.; McGhee, J.R. A dilemma for mucosal vaccination: Efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002, 20, 2431-2438.
187. Pizza, M.; Giuliani, M.; Fontana, M.; Monaci, E.; Douce, G.; Dougan, G.; Mills, K.; Rappuoli, R.; Del Giudice, G. Mucosal vaccines: Non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001, 19, 2534-2541.
188. Mutsch, M.; Zhou, W.; Rhodes, P.; Bopp, M.; Chen, R.T.; Linder, T.; Spyr, C.; Steffen, R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 2004, 350, 896-903.
189. Liang, S.; Hajishengallis, G. Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. Immunol. Investig. 2010, 39, 449-467.
190. Spangler, B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 1992, 56, 622-647.
191. Mata-Haro, V.; Cekic, C.; Martin, M.; Chilton, P.M.; Casella, C.R.; Mitchell, T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science Signal. 2007, 316, 1628.
192. Smith, K.A. T-cell growth factor. Immunol. Rev. 1980, 51, 337-357.
193. Kim, J.J.; Trivedi, N.N.; Nottingham, L.K.; Morrison, L.; Tsai, A.; Hu, Y.; Mahalingam, S.; Dang, K.; Ahn, L.; Doyle, N.K. et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J. Immunol. 1998, 28, 1089-1103.
194. Xin, K.-Q.; Hamajima, K.; Sasaki, S.; Tsuji, T.; Watabe, S.; Okada, E.; Okuda, K. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 1999, 17, 858-866.
195. Barouch, D.H.; Santra, S.; Schmitz, J.E.; Kuroda, M.J.; Fu, T.-M.; Wagner, W.; Bilska, M.; Craiu, A.; Zheng, X.X.; Krivulka, G.R. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290, 486-492.
196. Barouch, D.H.; Letvin, N.L.; Seder, R.A. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol. Rev. 2004, 202, 266-274.
197. Seaman, M.S.; Peyerl, F.W.; Jackson, S.S.; Lifton, M.A.; Gorgone, D.A.; Schmitz, J.E.; Letvin, N.L. Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J. Virol. 2004, 78, 206-215.
198. Jeon, B.Y.; Eoh, H.; Ha, S.J.; Bang, H.; Kim, S.C.; Sung, Y.C.; Cho, S.N. Co-immunization of plasmid DNA encoding IL-12 and IL-18 with Bacillus Calmette-Guerin vaccine against progressive tuberculosis. Yonsei Med. J. 2011, 52, 1008-1015.
199. Kim, J.J.; Nottingham, L.K.; Sin, J.I.; Tsai, A.; Morrison, L.; Oh, J.; Dang, K.; Hu, Y.; Kazahaya, K.; Bennett, M. et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J. Clin. Investig. 1998, 102, 1112-1124.
200. + T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J. Virol. 2000, 74, 11173-11180.
201. Barouch, D.H.; McKay, P.F.; Sumida, S.M.; Santra, S.; Jackson, S.S.; Gorgone, D.A.; Lifton, M.A.; Chakrabarti, B.K.; Xu, L.; Nabel, G.J. et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J. Virol. 2003, 77, 8729-8735.
202. Sumida, S.M.; McKay, P.F.; Truitt, D.M.; Kishko, M.G.; Arthur, J.C.; Seaman, M.S.; Jackson, S.S.; Gorgone, D.A.; Lifton, M.A.; Letvin, N.L. et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J. Clin. Investig. 2004, 114, 1334-1342.
203. Chang, D.Z.; Lomazow, W.; Joy Somberg, C.; Stan, R.; Perales, M.A. Granulocyte-macrophage colony stimulating factor: An adjuvant for cancer vaccines. Hematology 2004, 9, 207-215.
204. + T lymphocyte responses. Eur. J. Immunol. 2004, 34, 1011-1020.
205. Pavlenko, M.; Roos, A.K.; Lundqvist, A.; Palmborg, A.; Miller, A.M.; Ozenci, V.; Bergman, B.; Egevad, L.; Hellstrom, M.; Kiessling, R. et al. A Phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br. J. Cancer 2004, 91, 688-694.
206. Brave, A.; Ljungberg, K.; Boberg, A.; Rollman, E.; Isaguliants, M.; Lundgren, B.; Blomberg, P.; Hinkula, J.; Wahren, B. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol. Ther. 2005, 12, 1197-1205.
207. Drexler, H.G.; Quentmeier, H. FLT3: Receptor and ligand. Growth Factors 2004, 22, 71-73.
208. Sekine, S.; Kataoka, K.; Fukuyama, Y.; Adachi, Y.; Davydova, J.; Yamamoto, M.; Kobayashi, R.; Fujihashi, K.; Suzuki, H.; Curiel, D.T. et al. A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. J. Immunol. 2008, 180, 8126-8134.
209. Grant, E.V.; Thomas, M.; Fortune, J.; Klibanov, A.M.; Letvin, N.L. Enhancement of plasmid DNA immunogenicity with linear polyethylenimine. Eur. J. Immunol. 2012, 42, 2937-2948.
210. Waeckerle-Men, Y.; Groettrup, M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv. Drug Deliv. Rev. 2005, 57, 475-482.
211. Aspden, T.J.; Mason, J.D.; Jones, N.S.; Lowe, J.; Skaugrud, Ø.; Illum, L. Chitosan as a nasal delivery system: The effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J. Pharm. Sci. 1997, 86, 509-513.
212. Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer. Available online: http://clinicaltrials.gov/ct2/show/NCT00059605?term=NCT00059605&rank=1 (accessed on 20 June 2014).
213. Cheng, J.Y.; Huang, H.N.; Tseng, W.C.; Li, T.L.; Chan, Y.L.; Cheng, K.C.; Wu, C.J. Transcutaneous immunization by lipoplex-patch based DNA vaccines is effective vaccination against Japanese encephalitis virus infection. J. Control. Release 2009, 135, 242-249.
214. Chen, R.; Lu, S.H.; Tong, Q.B.; Lou, D.; Shi, D.Y.; Jia, B.B.; Huang, G.P.; Wang, J.F. Protective effect of DNA-mediated immunization with liposome-encapsulated GRA4 against infection of Toxoplasma gondii. J. Zhejiang Univ. Sci. B 2009, 10, 512-521.
215. Korsholm, K.S.; Andersen, P.L.; Christensen, D. Cationic liposomal vaccine adjuvants in animal challenge models: Overview and current clinical status. Expert Rev. Vaccines 2012, 11, 561-577.
216. Gustafson, G.L.; Rhodes, M.J. Bacterial cell wall products as adjuvants: Early interferon γ as a marker for adjuvants that enhance protective immunity. Res. Immunol. 1992, 143, 483-488.
217. Ulrich, J.T.; Myers, K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol. 1995, 6, 495-524.
218. Morrison, D.C.; Silverstein, R.; Luchi, M.; Shnyra, A. Structure-function relationships of bacterial endotoxins. Contribution to microbial sepsis. Infect. Dis. Clin. N. Am. 1999, 13, 313-340.
219. Lambrecht, B.N.; Kool, M.; Willart, M.A.; Hammad, H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 2009, 21, 23-29.
220. Manicassamy, S.; Pulendran, B. Modulation of adaptive immunity with Toll-like receptors. Semin. Immunol. 2009, 21, 185-193.
221. Evans, J.T.; Cluff, C.W.; Johnson, D.A.; Lacy, M.J.; Persing, D.H.; Baldridge, J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines 2003, 2, 219-229.
222. Childers, N.K.; Miller, K.L.; Tong, G.; Llarena, J.C.; Greenway, T.; Ulrich, J.T.; Michalek, S.M. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect. Immun. 2000, 68, 5509-5516.
223. Hall, M.A.; Stroop, S.D.; Hu, M.C.; Walls, M.A.; Reddish, M.A.; Burt, D.S.; Lowell, G.H.; Dale, J.B. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect. Immun. 2004, 72, 2507-2512.
224. Kamphuis, T.; Shafique, M.; Meijerhof, T.; Stegmann, T.; Wilschut, J.; de Haan, A. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats. Vaccine 2013, 31, 2169-2176.
225. Greenland, J.R.; Letvin, N.L. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007, 25, 3731-3741.
226. Heath, A.W. Cytokines as immunological adjuvants. Pharm. Biotechnol. 1995, 6, 645-658.
227. Thompson, A.L.; Staats, H.F. Cytokines: The future of intranasal vaccine adjuvants. Clin. Dev. Immunol. 2011, 2011, 289597.
228. Lynch, J.M.; Briles, D.E.; Metzger, D.W. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun. 2003, 71, 4780-4788.
229. Staats, H.F.; Bradney, C.P.; Gwinn, W.M.; Jackson, S.S.; Sempowski, G.D.; Liao, H.-X.; Letvin, N.L.; Haynes, B.F. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol. 2001, 167, 5386-5394.
230. Huber, V.C.; Arulanandam, B.P.; Arnaboldi, P.M.; Elmore, M.K.; Sheehan, C.E.; Kallakury, B.V.; Metzger, D.W. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int. Immunopharmacol. 2003, 3, 801-809.